Notice Annual General Meeting in ILYA PHARMA AB (publ) June 28 2024
The work is funded by Ilya Pharma AB, Bio-X grant from STUNS in Uppsala and the Knut and Alice Wallenberg Foundation.
The company is insourcing business administration.
CXCL12-expressing Limosilactobacillus reuteri has clinically relevant antimicrobial effects of multidrug-resistant bacteria isolated from wounds of war victims in Ukraine Presented by Dr Andreas Fasth Poster ID 939